Our consultants can support you to achieve the full compliance of your products.
Visit our Quality Compliance dedicated page or get in touch with us to learn how PQE Group can help your business.
ESG Manager @PQE Group
What Does ESG Mean In The Pharmaceutical Industry ?
In 2026, having sustainability initiatives in place is no longer enough for pharmaceutical businesses to claim they are sustainable. To demonstrate how effective these initiatives are, companies are now required to measure and report their impact in a transparent and clear manner. Organizations that approach ESG as a strategic framework to assess the social, environmental, and governance impact of their pharmaceutical operations, rather than treating it as a simple checkbox or a tool to greenwash their image, are attracting more investment, top-tier talent, and strengthening their reputation compared with their competitors.
ESG Reporting Regulations In Life Sciences
Many EU companies and companies with offices in the EU are required to disclose information regarding the impact of their operations on ESG, a move that transforms sustainability reporting from voluntary to mandatory for certain businesses. Pharmaceutical companies with a presence in Europe, when disclosing their sustainability performance, must adhere to specific Sustainability Reporting Standards and report on key topics such as carbon emissions, pollution and waste, labor practices, anti-corruption policies, and human rights in supply chains, among others.
Impact Of Regulatory Changes On Compliance In Life Sciences
The shift from voluntary to mandatory ESG reporting is already affecting how pharmaceutical businesses, and life sciences organizations more broadly, operate and interact with the environment and the communities in which they work. As companies that invest immense resources in improving people’s lives, it is only right that these efforts do not come at a cost to the environment or local communities. Regulatory requirements bring a range of benefits to both stakeholders and businesses, chief among them transparency and industry-wide consistency. By making sustainability a measurable metric that can be analyzed quantitatively, they enable stakeholders to evaluate a company from both a financial and sustainability perspective and make informed decisions. Moreover, we have to take into account that many parallel industries such as consulting are not required to by law to comply with these regulatory requirements, however they are expected to meet these obligatory requirements by their large clients.
Current Challenges In ESG Reporting Regulations
The pharmaceutical industry is complex and highly regulated, and when the many stakeholders and suppliers that make up its intricate supply chains are considered, it becomes clear that implementing effective ESG reporting regulations is a significant challenge, though not an impossible one. To provide an accurate picture of their sustainability performance, pharmaceutical companies must collect both internal and external data, including third-party supplier data from across the entire supply chain, and ensure that this information is processed and reported in line with the regulatory requirements. Another major challenge pharmaceutical companies face is determining what constitutes a material sustainability issue for the business and how it should be measured.
The Way Forward
Regardless of the challenges currently faced by pharmaceutical companies in ESG reporting, it does not change the fact that these businesses consume immense resources and impact local communities through their operations. For the industry to continue saving and improving lives in a sustainable manner, there must be a greater emphasis on ESG across the entire value chain, from the way resources are sourced to how they are utilized and disposed of, as well as how businesses engage with their employees and society. Pharmaceutical companies must seek sustainable ways to expand access to medicines and address current industry challenges while ensuring that innovation and financial gains do not come at the expense of environmental protection, ethical governance, or social responsibility.
